Valuation
- Market cap
- 46,617,000
- Revenue TTM
- $0
- Net income TTM
- $-90,970,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 1,691,100
- Avg volume
- 2,460,316
- Day's range
- $0.93 – $1.04
- Shares out
- 48,308,000
- Stochastic %K
- 36%
- Beta
- -0.65
- Analysts
- Strong Sell
- Price target
- $6.50
Company profile
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of bl...
Show more
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 512 501 2444
- Website
- https://www.filanatx.com
- Address
- 6801 N. Capital of Texas Highway, Building 1, Austin, United States
Latest news
No headlines yet.
